NCT07505004Phase 3Active not recruiting

Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

Study sponsor: Praxis Precision Medicines

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-01Estimated

Enrollment · participants300Estimated

Source updated2026-08-03Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-08-03 · 1 field changed

Recruitment status

Recorded edit

− Previous value

Recruiting

+ Updated value

Active not recruiting

Check registry source

Study details

Conditions studied

Focal Epilepsy

Treatments or interventions studied

40 mg/day vormatrogine for 12 weeksDrug
30 mg/day vormatrogine for 12 weeksDrug
20 mg/day vormatrogine for 12 weeksDrug
PlaceboDrug

Primary outcomes · main study measures

measure: To evaluate the efficacy of vormatrigine compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs; description: Median percent change in monthly (28 days) focal seizure frequency from the Screening/Observation Period to the Treatment Period for vormatrogine compared to placebo.; timeFrame: 12 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history